Abstract
Canine mammary tumor is the most common neoplasm in female dogs, and it has generated considerable attention as a translational model for human breast cancer. Ser/Thr protein phosphatase 2A (PP2A) plays a critical role as a tumor suppressor, and SET/I2PP2A, the endogenous inhibitory protein of PP2A, binds directly to PP2A and suppresses its phosphatase activity. Here, we investigated the role of SET in the tumorigenic growth in canine mammary tumor as well as in the sensitivity of tumors to existing therapeutics. Elevated protein levels of SET were observed in advanced-stage of canine mammary tumor tissues of dogs compared with paired normal tissues. Knockdown of SET expression in a canine mammary tumor cell line CIP-m led to increased PP2A activity and decreased cell proliferation, colony formation, and in vivo tumor growth. We observed suppression of mTOR, β-catenin, and NFκB signaling by SET knockdown. The sensitivity of CIP-m cells to doxorubicin was decreased by SET knockdown, while SET knockdown in CIP-m cells did not affect sensitivity to 4-OH-tamoxifen, carboplatin, bortezomib, and X-ray radiation. These data suggest that SET plays important roles in the tumor progression of a subset of canine mammary tumor by suppressing PP2A activity and enhancing mTOR, β-catenin, and NFκB signaling.
Highlights
Canine mammary tumor is one of the most common diseases in small animal medicine and accounts for ~40% of tumors in female dogs
We show that SET protein levels are elevated in canine breast cancer tissues, and that knockdown of SET expression in a canine mammary tumor cell line of metastatic origin leads to increase in phosphatase 2A (PP2A) activity and decreases in cell proliferation, colony formation, and anchorage-independent cell growth
SET protein levels are enhanced in advanced-stage of canine mammary tumor tissues and cell lines
Summary
Canine mammary tumor is one of the most common diseases in small animal medicine and accounts for ~40% of tumors in female dogs. Her2-positive human breast cancer, tyrosine kinase inhibitors have been shown to have certain therapeutic effect. Enhanced SET expression has been observed in many human tumors including breast cancer, chronic myeloid leukemia, and B-cell non-Hodgkin lymphoma, and SET expression levels have been shown to correlate positively with poor prognosis of chronic myeloid leukemia[15, 16]. In human breast cancer, increased SET protein level has been reported to lead to c-Myc stabilization[16]. We show that SET protein levels are elevated in canine breast cancer tissues, and that knockdown of SET expression in a canine mammary tumor cell line of metastatic origin leads to increase in PP2A activity and decreases in cell proliferation, colony formation, and anchorage-independent cell growth. We further analyzed the effects of SET KD on the sensitivity of tumors to existing therapeutics
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
